How to optimise RAASi therapy in patients with hyperkalaemia
15 December 2021, from
Heart Failure Association of the ESC (HFA)
Doctor A. Rakisheva (Almaty, KZ)
Professor L. Lund (Stockholm, SE)
Professor G. Rosano (London, GB)
Needs assessment and expected educational outcome
To update evaluations for iron deficiency and therapeutic iron supplementation, according to the new 2021 ESC/HFA Guidelines for Heart Failure; to gain insights from the AFFIRM-AHF trial; to learn about cost effectiveness of iron supplementation in HF patients; and to learn the effect of iron supplementation on exercise capacity and QoL.
After watching this webinar, participants will :
be updated on the epidemiology of hypokalaemia and hyperkalaemia;
learn when and how to monitor/measure K levels in heart failure; and
learn how to evaluate management options in patients at risk of hyperkalaemia, including new therapies that may improve adherence and treatment optimisation in patients with heart failure and high K levels.
This programme is supported by Vifor Pharma in the form of an educational grant. The scientific programme has not been influenced in any way by its sponsors.
This webinar is designed for general cardiologists and all healthcare professionals interested in Heart Failure.
During the webinar, you will be encouraged to send your questions by chat and interact with our key opinion leaders who will provide live feedback.
The webinar is available on PC and tablets. The use of a smartphone is not recommended.
To answer the MCQs during the live, you must allow pop-up windows.
A high-speed Internet connection is required (minimum 2 Mbps).